Inozyme gets Fast Track status for candidate for rare calcification condition
2024-07-02
JHVEPhoto The U.S. FDA has granted Inozyme Pharma (NASDAQ:INZY) Fast Track designation for NZ-701, its treatment of ABCC6 Deficiency. The company noted it hopes to have an agreement with regulators on a pivotal trial design by the end of the year. In April, Inozyme released promising topline results from anContinue Reading
